Evaluation of the Live Biotherapeutic Product, Asymptomatic Bacteriuria Escherichia coli 2-12, in Healthy Dogs and Dogs with Clinical Recurrent UTI

G. Segev, Jane E Sykes, D. J. Klumpp, A. J. Schaeffer, E. M. Antaki, Barbara A Byrne, R. E. Yaggie, Joellen L Westropp

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Antimicrobial resistance is an emerging problem. Hypothesis/Objective: To investigate the safety and efficacy of a live biotherapeutic product, ASB E. coli 2-12 for UTI treatment. Animals: Six healthy research dogs; nine client-owned dogs with recurrent UTI. Methods: Prospective noncontrolled clinical trial. For safety data, research dogs were sedated, a urinary catheter was inserted into the bladder; 1010 CFU/mL of ASB E. coli 2-12 was instilled. Urine was cultured on days 1, 3, and 8 post-instillation and dogs were observed for lower urinary tract signs (LUTS). For client-owned dogs, ASB E. coli 2-12 was instilled similarly and urine cultures analyzed on days 1, 7, and 14 days postinstillation. Results: No LUTS were noted in any of the 6 research dogs after ASB E. coli 2-12 infusion. Pulse field gel electrophoresis (PFGE) studies confirmed the bacterial strains isolated matched that ASB E. coli 2-12 strain. Four of the nine client-owned dogs had complete or nearly complete clinical cures by day 14. Of these four dogs, 3 also had microbiologic cures at day 14; one of these dogs had subclinical bacteriuria (in addition to ASB E. coli 2-12). Three of these four dogs had ASB E. coli 2-12 isolated from their urine at day 14. With the exception of mild, temporary, self-limiting, hyporexia in two dogs on the day of biotherapeutic administration, there were no major adverse effects. Conclusions and Clinical Importance: These results suggest ASB E. coli 2-12 is safe and should be investigated in a larger controlled study evaluating clinical UTI in dogs.

Original languageEnglish (US)
Pages (from-to)267-273
Number of pages7
JournalJournal of Veterinary Internal Medicine
Volume32
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Bacteriuria
Dogs
Escherichia coli
dogs
urine
urinary tract
Urine
Urinary Tract
Research
Safety
Urinary Catheters
prospective studies
bladder
catheters
antibiotic resistance
gel electrophoresis
Electrophoresis
clinical trials
Urinary Bladder
Gels

Keywords

  • Antimicrobial resistance
  • Cystitis
  • Dog
  • Urinary tract

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Evaluation of the Live Biotherapeutic Product, Asymptomatic Bacteriuria Escherichia coli 2-12, in Healthy Dogs and Dogs with Clinical Recurrent UTI. / Segev, G.; Sykes, Jane E; Klumpp, D. J.; Schaeffer, A. J.; Antaki, E. M.; Byrne, Barbara A; Yaggie, R. E.; Westropp, Joellen L.

In: Journal of Veterinary Internal Medicine, Vol. 32, No. 1, 01.01.2018, p. 267-273.

Research output: Contribution to journalArticle

@article{9b817ddb00ba4a6c92d8298fa31f54ac,
title = "Evaluation of the Live Biotherapeutic Product, Asymptomatic Bacteriuria Escherichia coli 2-12, in Healthy Dogs and Dogs with Clinical Recurrent UTI",
abstract = "Background: Antimicrobial resistance is an emerging problem. Hypothesis/Objective: To investigate the safety and efficacy of a live biotherapeutic product, ASB E. coli 2-12 for UTI treatment. Animals: Six healthy research dogs; nine client-owned dogs with recurrent UTI. Methods: Prospective noncontrolled clinical trial. For safety data, research dogs were sedated, a urinary catheter was inserted into the bladder; 1010 CFU/mL of ASB E. coli 2-12 was instilled. Urine was cultured on days 1, 3, and 8 post-instillation and dogs were observed for lower urinary tract signs (LUTS). For client-owned dogs, ASB E. coli 2-12 was instilled similarly and urine cultures analyzed on days 1, 7, and 14 days postinstillation. Results: No LUTS were noted in any of the 6 research dogs after ASB E. coli 2-12 infusion. Pulse field gel electrophoresis (PFGE) studies confirmed the bacterial strains isolated matched that ASB E. coli 2-12 strain. Four of the nine client-owned dogs had complete or nearly complete clinical cures by day 14. Of these four dogs, 3 also had microbiologic cures at day 14; one of these dogs had subclinical bacteriuria (in addition to ASB E. coli 2-12). Three of these four dogs had ASB E. coli 2-12 isolated from their urine at day 14. With the exception of mild, temporary, self-limiting, hyporexia in two dogs on the day of biotherapeutic administration, there were no major adverse effects. Conclusions and Clinical Importance: These results suggest ASB E. coli 2-12 is safe and should be investigated in a larger controlled study evaluating clinical UTI in dogs.",
keywords = "Antimicrobial resistance, Cystitis, Dog, Urinary tract",
author = "G. Segev and Sykes, {Jane E} and Klumpp, {D. J.} and Schaeffer, {A. J.} and Antaki, {E. M.} and Byrne, {Barbara A} and Yaggie, {R. E.} and Westropp, {Joellen L}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/jvim.14851",
language = "English (US)",
volume = "32",
pages = "267--273",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Evaluation of the Live Biotherapeutic Product, Asymptomatic Bacteriuria Escherichia coli 2-12, in Healthy Dogs and Dogs with Clinical Recurrent UTI

AU - Segev, G.

AU - Sykes, Jane E

AU - Klumpp, D. J.

AU - Schaeffer, A. J.

AU - Antaki, E. M.

AU - Byrne, Barbara A

AU - Yaggie, R. E.

AU - Westropp, Joellen L

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Antimicrobial resistance is an emerging problem. Hypothesis/Objective: To investigate the safety and efficacy of a live biotherapeutic product, ASB E. coli 2-12 for UTI treatment. Animals: Six healthy research dogs; nine client-owned dogs with recurrent UTI. Methods: Prospective noncontrolled clinical trial. For safety data, research dogs were sedated, a urinary catheter was inserted into the bladder; 1010 CFU/mL of ASB E. coli 2-12 was instilled. Urine was cultured on days 1, 3, and 8 post-instillation and dogs were observed for lower urinary tract signs (LUTS). For client-owned dogs, ASB E. coli 2-12 was instilled similarly and urine cultures analyzed on days 1, 7, and 14 days postinstillation. Results: No LUTS were noted in any of the 6 research dogs after ASB E. coli 2-12 infusion. Pulse field gel electrophoresis (PFGE) studies confirmed the bacterial strains isolated matched that ASB E. coli 2-12 strain. Four of the nine client-owned dogs had complete or nearly complete clinical cures by day 14. Of these four dogs, 3 also had microbiologic cures at day 14; one of these dogs had subclinical bacteriuria (in addition to ASB E. coli 2-12). Three of these four dogs had ASB E. coli 2-12 isolated from their urine at day 14. With the exception of mild, temporary, self-limiting, hyporexia in two dogs on the day of biotherapeutic administration, there were no major adverse effects. Conclusions and Clinical Importance: These results suggest ASB E. coli 2-12 is safe and should be investigated in a larger controlled study evaluating clinical UTI in dogs.

AB - Background: Antimicrobial resistance is an emerging problem. Hypothesis/Objective: To investigate the safety and efficacy of a live biotherapeutic product, ASB E. coli 2-12 for UTI treatment. Animals: Six healthy research dogs; nine client-owned dogs with recurrent UTI. Methods: Prospective noncontrolled clinical trial. For safety data, research dogs were sedated, a urinary catheter was inserted into the bladder; 1010 CFU/mL of ASB E. coli 2-12 was instilled. Urine was cultured on days 1, 3, and 8 post-instillation and dogs were observed for lower urinary tract signs (LUTS). For client-owned dogs, ASB E. coli 2-12 was instilled similarly and urine cultures analyzed on days 1, 7, and 14 days postinstillation. Results: No LUTS were noted in any of the 6 research dogs after ASB E. coli 2-12 infusion. Pulse field gel electrophoresis (PFGE) studies confirmed the bacterial strains isolated matched that ASB E. coli 2-12 strain. Four of the nine client-owned dogs had complete or nearly complete clinical cures by day 14. Of these four dogs, 3 also had microbiologic cures at day 14; one of these dogs had subclinical bacteriuria (in addition to ASB E. coli 2-12). Three of these four dogs had ASB E. coli 2-12 isolated from their urine at day 14. With the exception of mild, temporary, self-limiting, hyporexia in two dogs on the day of biotherapeutic administration, there were no major adverse effects. Conclusions and Clinical Importance: These results suggest ASB E. coli 2-12 is safe and should be investigated in a larger controlled study evaluating clinical UTI in dogs.

KW - Antimicrobial resistance

KW - Cystitis

KW - Dog

KW - Urinary tract

UR - http://www.scopus.com/inward/record.url?scp=85040992044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040992044&partnerID=8YFLogxK

U2 - 10.1111/jvim.14851

DO - 10.1111/jvim.14851

M3 - Article

C2 - 29243301

AN - SCOPUS:85040992044

VL - 32

SP - 267

EP - 273

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 1

ER -